Paul Pochtar's guest appearances

Paul Pochtar

Relentless Health Value™

Mark Cuban

Kyle Samani

David Smith

Michael Hunt

Marty Makary

Mike Rea

Laura Adams

Erik Davis

Jason Rose

Johns Hopkins

James Grant

Lisa Simpson

George Mathew

John Moore

Jennifer Miller

OwlTail

David Guy

Prior to Aventria, David held several commercial leadership roles, including Head of Oncology Marketing at Genentech and VP Strategic Marketing at Schering AG, specializing in commercializing oncology and specialty products. He was also instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan. Paul has extensive experience leading successful market access commercialization strategies of specialty pharmaceuticals throughout their life cycles, including several landmark oncology products and other specialty therapeutics. Paul is a former Vice President of Payer Marketing with Bayer and former Vice President and Head of Oncology Managed Markets and Market Access at Novartis Pharmaceuticals. He is an RPh and a graduate of Rutgers University's Ernest Mario College of Pharmacy. 00:00 The trends affecting market access to oncology. 02:00 Innovations in oncology. 02:20 Immuno-oncology. 03:50 How treatment has improved with these oncology innovations. 05:45 The implications of patients getting access to these new treatment options. 07:20 Answering 3 questions around these oncology innovations. 10:05 Outcomes-based contracts and biomarker testing. 11:30 Risk-based contracts. 12:15 Indication-based pricing 14:45 “How do we make access to novel specialty drugs more affordable for the actual patient.” - Paul Pochtar 17:50 How various biomarkers fit in together. 18:15 Determining what biomarkers are relevant. 19:00 Pathways and guidelines being derived from Real World Evidence. 20:45 “There’s no standardized approach.” - David Guy 23:40 How a pathway gets used. 29:35 Alternative payment models. 30:15 “As we look for a solution, it’s not one entity that has the answer.” - Paul 30:45 Innovation, cost challenge, decision-making process. 32:38 “The elephant in the room is the co-pay burdens.” - David 32:57 Why is a co-pay applicable for a cancer patient? 33:33 Andrew Schorr of Patient Power - EP145.

Prior to Aventria, David held several commercial leadership roles, including Head of Oncology Marketing at Genentech and VP Strategic Marketing at Schering AG, specializing in commercializing oncology and specialty products. He was also instrumental in the commercialization of Taxotere, Fludara, Herceptin, and Rituxan. Paul has extensive experience leading successful market access commercialization strategies of specialty pharmaceuticals throughout their life cycles, including several landmark oncology products and other specialty therapeutics. Paul is a former Vice President of Payer Marketing with Bayer and former Vice President and Head of Oncology Managed Markets and Market Access at Novartis Pharmaceuticals. He is an RPh and a graduate of Rutgers University's Ernest Mario College of Pharmacy. 00:00 The trends affecting market access to oncology. 02:00 Innovations in oncology. 02:20 Immuno-oncology. 03:50 How treatment has improved with these oncology innovations. 05:45 The implications of patients getting access to these new treatment options. 07:20 Answering 3 questions around these oncology innovations. 10:05 Outcomes-based contracts and biomarker testing. 11:30 Risk-based contracts. 12:15 Indication-based pricing 14:45 “How do we make access to novel specialty drugs more affordable for the actual patient.” - Paul Pochtar 17:50 How various biomarkers fit in together. 18:15 Determining what biomarkers are relevant. 19:00 Pathways and guidelines being derived from Real World Evidence. 20:45 “There’s no standardized approach.” - David Guy 23:40 How a pathway gets used. 29:35 Alternative payment models. 30:15 “As we look for a solution, it’s not one entity that has the answer.” - Paul 30:45 Innovation, cost challenge, decision-making process. 32:38 “The elephant in the room is the co-pay burdens.” - David 32:57 Why is a co-pay applicable for a cancer patient? 33:33 Andrew Schorr of Patient Power - EP145.

EP175: A Market Access Oncology Trend Report, With David Guy and Paul Pochtar From Aventria

Paul Pochtar is an industry leader who has more than 25 years of extensive experience leading the successful commercialization of specialty pharmaceuticals throughout their lifecycle, including several landmark oncology products and other specialty therapeutics. He has been instrumental in developing innovative brand value propositions that resonate with government and commercial payers and in the execution of market introductions by designing novel distribution, dispensing, and patient services models. He has strong operational proficiency and a keen ability to mobilize both Pharma functional skill centers and channel partners to build plans, structures, and processes to efficiently execute strategies. Paul has enjoyed a distinguished career with Bayer Pharmaceuticals as Vice President of Payer Marketing and with Novartis Pharmaceuticals as Vice President &amp; Head of Oncology Managed Markets and Market Access. He is a graduate of Rutgers University Ernest Mario College of Pharmacy and is a registered pharmacist in New Jersey and Pennsylvania. He can be reached at paulpochtar@gmail.com 00:00 Paul discusses the changes in the healthcare industry from the Pharma viewpoint. 01:15 Paul breaks down these changes step by step. 02:10 How these changes are impacting Pharma on a larger scale. 03:30 What failure means in the Pharma perspective. 04:25 The issue of needing clear criteria. 05:35 From the Pharma perspective, why companies need to be laying out very strong value proposition. 06:30 From the Pharma perspective, companies need to be laying out a very strong value proposition. 07:40 The right balance of the marketing mix, and what this is for Pharma business in healthcare. 08:35 “Copay is all about supply and demand.” 09:40 The need to think about the business Pharma is truly in, in order to improve patient care. 10:15 Paul discusses successful and non-successful business models that he has come across over the years. 11:40 Paul talks about some of the advanced formulary decision-making criteria for clinical trials hoping to get FDA approval. 14:50 Patient population and how this fluctuates according to the data that a Pharma company has. 16:50 How Pharma is equipped to work with the constant change of decision-makers within healthcare. 18:00 Consolidation within Pharma and how it benefits patient care and healthcare in general. 21:15 How hospitals are changing their infrastructures with population in mind. 23:20 Paul gives his advice to Pharma organizations attempting to navigate their businesses. 24:00 The four things Pharma needs to consider when a manufacturer wants to change. 24:30 Why a comprehensive strategy is most important in considering change within a Pharma company. 27:00 Engaging high-risk patients. 30:00 Which organizations need consideration for having a different collaborating relationship with patients, and how patients are really struggling in the marketplace.

Paul Pochtar is an industry leader who has more than 25 years of extensive experience leading the successful commercialization of specialty pharmaceuticals throughout their lifecycle, including several landmark oncology products and other specialty therapeutics. He has been instrumental in developing innovative brand value propositions that resonate with government and commercial payers and in the execution of market introductions by designing novel distribution, dispensing, and patient services models. He has strong operational proficiency and a keen ability to mobilize both Pharma functional skill centers and channel partners to build plans, structures, and processes to efficiently execute strategies. Paul has enjoyed a distinguished career with Bayer Pharmaceuticals as Vice President of Payer Marketing and with Novartis Pharmaceuticals as Vice President &amp; Head of Oncology Managed Markets and Market Access. He is a graduate of Rutgers University Ernest Mario College of Pharmacy and is a registered pharmacist in New Jersey and Pennsylvania. He can be reached at <a href="mailto:paulpochtar@gmail.com">paulpochtar@gmail.com</a> 00:00 Paul discusses the changes in the healthcare industry from the Pharma viewpoint. 01:15 Paul breaks down these changes step by step. 02:10 How these changes are impacting Pharma on a larger scale. 03:30 What failure means in the Pharma perspective. 04:25 The issue of needing clear criteria. 05:35 From the Pharma perspective, why companies need to be laying out very strong value proposition. 06:30 From the Pharma perspective, companies need to be laying out a very strong value proposition. 07:40 The right balance of the marketing mix, and what this is for Pharma business in healthcare. 08:35 “Copay is all about supply and demand.” 09:40 The need to think about the business Pharma is truly in, in order to improve patient care. 10:15 Paul discusses successful and non-successful business models that he has come across over the years. 11:40 Paul talks about some of the advanced formulary decision-making criteria for clinical trials hoping to get FDA approval. 14:50 Patient population and how this fluctuates according to the data that a Pharma company has. 16:50 How Pharma is equipped to work with the constant change of decision-makers within healthcare. 18:00 Consolidation within Pharma and how it benefits patient care and healthcare in general. 21:15 How hospitals are changing their infrastructures with population in mind. 23:20 Paul gives his advice to Pharma organizations attempting to navigate their businesses. 24:00 The four things Pharma needs to consider when a manufacturer wants to change. 24:30 Why a comprehensive strategy is most important in considering change within a Pharma company. 27:00 Engaging high-risk patients. 30:00 Which organizations need consideration for having a different collaborating relationship with patients, and how patients are really struggling in the marketplace.

Episode 64: Show Me The Value--Pharma’s Quest To Capture And Communicate The Value Drugs Deliver with Paul Pochtar